Actively Recruiting
A Study on COPD Phenotypes, Endotypes and Treatable Traits in Hong Kong Patients Observational 3-Year Study on Patient Outcomes and Treatable Traits
Led by Chinese University of Hong Kong · Updated on 2025-05-04
460
Participants Needed
1
Research Sites
52 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic Obstructive Pulmonary Disease (COPD) is a complex and progressive lung condition with varying types and characteristics, including different phenotypes and endotypes. This research aims to study these variations and treatable traits in COPD patients in Hong Kong, where healthcare differs from other regions. The study will observe how these traits change over time and how they relate to patient outcomes like exacerbations, mortality, lung function decline, symptoms, and quality of life over a period of three years. Participants will be recruited from outpatient and inpatient settings at a hospital. This prospective observational study includes an initial baseline assessment covering demographics, lung function tests, breath and blood biomarkers, exercise capacity, symptoms, treatment history, and healthcare use. Follow-up includes telephone assessments every six months for exacerbation history and annual visits for repeated lung function and biomarker tests, symptom evaluations, and health status updates for three years. During the study, researchers will gather data through spirometry, exhaled nitric oxide measurements, breath and blood sample collections, questionnaires on symptoms and quality of life, and records of exacerbations and mortality. This detailed monitoring will help identify treatable traits and patient groups with similar features, aiming to better understand COPD progression and management in this population.
CONDITIONS
Brief Title
A Study on COPD Phenotypes, Endotypes and Treatable Traits
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient diagnosed with COPD based on chronic respiratory symptoms and lung function showing post-bronchodilator FEV1/FVC ratio less than 70%
- Age 40 years or older
You will not qualify if you...
- Presence of serious diseases that prevent follow-up for 3 years, such as late-stage cancer, severe heart failure, or severe kidney failure not on dialysis
- Unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants undergo baseline assessments including spirometry, breath tests, blood biomarkers, and questionnaires to characterize COPD phenotypes, endotypes, and treatable traits.
1 baseline visit (in-person)
Duration - 3 years
Participants are monitored over 3 years with telephone follow-ups every 6 months and annual in-person visits to track COPD progression, exacerbations, lung function, and quality of life.
Telephone follow-up every 6 months and annual in-person visits at years 1, 2, and 3
Trial Site Locations
Total: 1 location
1
The Chinese University of Hong Kong
Hong Kong, Hong Kong
Actively Recruiting
Research Team
F
Fanny WS Ko, MD
D
David SC Hui, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here